Half-year report · Q2
4587.TEDINET S100WHGM
Period2025-01-01 → 2025-06-30
Filed2025-08-07
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.5bn | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥46.7bn | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥36.1bn | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Operating income | −¥2.6bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥24.6bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | −¥2.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥20.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥24.7bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥17.9bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | −¥2.1bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥15.0bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss IFRS (5-year summary) |
| Net income | ¥17.9bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥78.5bn | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥92.8bn | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥95.9bn | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥24.9bn | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥36.0bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥53.7bn | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥56.8bn | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥58.8bn | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥40.3bn | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥53.7bn | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥56.8bn | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥58.8bn | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥33.3bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥48.1bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥25.5bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥19.5bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | −¥11.0bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥23.8bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | −¥2.7bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥1.3bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | ¥8.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | ¥10.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥2.5bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥3.0bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥1.5bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥115.85 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥138.3 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥-16.4 | 2025-01-01 → 2025-06-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥115.68 | 2024-01-01 → 2024-12-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥138.11 | 2024-01-01 → 2024-06-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 68.3% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.2% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 61.3% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 26
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥453m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥453m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥761m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥761m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | −¥3.0bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥8.2bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥7.8bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥436m |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥9.0bn |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥8.5bn |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥453m |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | −¥2.6bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥178m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥178m |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥28.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥28.5bn |
| jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥24.7bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥7.8bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥7.7bn |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥178m |
| jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segment | segment profit | 2024-01-01 → 2024-06-30 | −¥47m |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥36.3bn |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥36.1bn |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥178m |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥24.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 582
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | CurrentQuarterInstant_No10MajorShareholdersMember | Original text (Japanese)P.O.BOX 351 BOSTON MASSACHUSETTS 02101 USA （東京都港区港南２丁目15-1） | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)ペプチドリーム株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)神奈川県川崎市川崎区殿町三丁目25番23号 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Description of fact that consolidated financial statements have been prepared in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | CurrentYTDDuration | Original text (Japanese)当社の中間連結財務諸表は第一種中間連結財務諸表であります。 | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc and internal system to prepare consolidated financial statements etc fairly in accordance with IFRS financial information | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of financial position IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of profit or loss IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed year to quarter end consolidated statement of comprehensive income IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of changes in equity IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Condensed quarterly consolidated statement of cash flows IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes reporting entity condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes basis of preparation condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant accounting policies condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes earnings per share condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes financial instruments condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes contingent liabilities condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Notes subsequent events condensed quarterly consolidated financial statements IFRS (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |